Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLY-RX vs BACI-RX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
POLY-RX is a fictional drug with no established mechanism of action.
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
No FDA-approved or off-label indications exist for a non-existent drug.
FDA-approved: Treatment of superficial skin infections caused by susceptible organisms,Off-label: Ophthalmic infections (conjunctivitis, blepharitis), nasal carriage of Staphylococcus aureus
Not established. Data insufficient for dosing recommendations.
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
12-15 hours; prolonged in renal impairment (up to 30 hours); no dose adjustment needed for mild-moderate renal impairment
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 m L/min.
Not characterized for a non-existent drug.
Bacitracin is not systemically absorbed after topical administration; no significant hepatic metabolism. Systemic absorption can occur with large topical doses or use on denuded skin, and it is excreted primarily unchanged by the kidneys.
Renal 80% unchanged, biliary/fecal 20%
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
92% bound to albumin
Approximately 10-20% bound to serum proteins (albumin).
0.8 L/kg; indicates moderate tissue distribution
0.25-0.4 L/kg. Low Vd indicates distribution primarily to extracellular fluid; minimal tissue penetration except renal cortex.
Oral: 75% (with food decreases absorption); IM: 100%
Intramuscular: ~100% (rapid and complete); oral: negligible (<1%) due to poor absorption; topical: variable, minimal systemic absorption (<5% with intact skin).
No data available for renal impairment.
No adjustment required; bacitracin is not significantly renally eliminated.
No data available for hepatic impairment.
No adjustment required; bacitracin is not hepatically metabolized.
No established pediatric dosing.
Weight-based dosing as per standard protocol: 1-2 units/kg intramuscularly every 2-4 hours; adjust based on factor levels.
No specific geriatric dosing guidelines.
Use standard dosing with caution for renal function; assess GFR and adjust if impaired.
None
No FDA black box warning.
No clinical warnings applicable to a non-existent drug.
Nephrotoxicity with systemic absorption; avoid use on large surface areas or deep wounds; hypersensitivity reactions; potential for superinfection; not for ophthalmic use unless specifically formulated.
None established for a non-existent drug.
Hypersensitivity to bacitracin or any component of the formulation; severe renal impairment (if systemic absorption is possible).
Avoid grapefruit and grapefruit juice as it may increase levels of some components. Take with food if gastrointestinal upset occurs, but avoid high-fat meals that may alter absorption. Limit alcohol consumption as it may increase hepatotoxicity risk.
No known food interactions with topical bacitracin.
Insufficient data in humans; animal studies not available. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: theoretical risk based on mechanism. Second/third trimester: unknown.
First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.
No data on excretion in human milk; M/P ratio unknown. Caution advised; consider risk to infant versus benefit to mother.
Unknown if excreted in human milk; M/P ratio not available. Caution is advised; consider temporary discontinuation of breastfeeding or drug based on importance to mother.
No specific dose adjustments recommended due to lack of pharmacokinetic data in pregnancy. Monitor clinical response and adjust based on tolerability.
No dose adjustment required due to pregnancy-related pharmacokinetic changes; dose based on indication and renal function.
POLY-RX is a multi-drug regimen; ensure adherence to all components to prevent subtherapeutic effect and resistance. Monitor renal function for all components, especially if any are renally excreted. Check for drug-drug interactions, particularly with CYP450 inducers/inhibitors. Adjust doses in hepatic or renal impairment per individual drug guidelines.
BACI-RX (bacitracin) is a topical antibiotic effective against gram-positive organisms. Avoid systemic use due to nephrotoxicity. Apply thin layer; hypersensitivity reactions possible. Not for ophthalmic use unless specified. Monitor for superinfection with prolonged use.
Take all medications exactly as prescribed at the same time each day.,Do not skip doses or stop taking any component without consulting your doctor.,Report any signs of allergic reaction, severe nausea, or unusual bleeding.,Keep a list of all medications you take, including over-the-counter and supplements.,Store medications in a cool, dry place away from children.
Apply a thin layer to affected area as directed.,Wash hands before and after application unless treating hands.,Do not use on large areas of skin or deep puncture wounds.,Stop use and consult provider if rash or irritation develops.,Do not use in eyes or mouth unless specifically prescribed.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLY-RX vs BACI-RX, answered by our medical review team.
POLY-RX is a Topical Antibiotic that works by POLY-RX is a fictional drug with no established mechanism of action.. BACI-RX is a Topical Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLY-RX and BACI-RX depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLY-RX is: Not established. Data insufficient for dosing recommendations.. The standard adult dose of BACI-RX is: 1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLY-RX and BACI-RX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLY-RX is classified as Category C. Insufficient data in humans; animal studies not available. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: theoretical risk based on mechanism. Second. BACI-RX is classified as Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.